Chile’s former top drug regulator says faster approvals mean little if coverage stalls, and wants the medicines agency separated administratively from the Institute of Public Health.
Chile’s former top drug regulator says faster approvals mean little if coverage stalls, and wants the medicines agency separated administratively from the Institute of Public Health.
Chile’s 2027 budget bill trims the Ley Ricarte Soto line to CLP 166,951m while health spending rises 4.7% in real terms, signalling little room for new high-cost therapies.
Chileans spend nearly US$100 million a year on weight-loss treatment, according to La Tercera, as seven generic semaglutide applications — including Laboratorio Chile’s Selfix — await regulatory review, putting Novo …
You must be logged in to post a comment.